Drug Profile
Research programme: tissue protection technology - Lundbeck/Warren Pharmaceuticals
Alternative Names: Tissue protection technology research programme - Warren Pharmaceuticals/Lundbeck; Tissue-protective cytokinesLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Warren Pharmaceuticals
- Developer Lundbeck A/S; Warren Pharmaceuticals
- Class Cytokines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders in USA
- 23 Oct 2007 A lead compound from this research programme enters clinical trials